Results 161 to 170 of about 15,116 (246)

Observations on an Open‐Label Phase 1/2 Dopamine Gene Therapy Trial (OXB‐102/Axo‐Lenti‐PD) in People with Parkinson's Disease

open access: yesMovement Disorders, EarlyView.
Abstract Background SUNRISE‐PD was a dose‐escalating, phase 1/2 study investigating a second‐generation lentiviral vector gene therapy delivering the genes for dopamine synthesis (OXB‐102) to treat Parkinson's disease (PD). The trial was prematurely terminated due to insolvency of the sponsor.
Simon Rowe   +19 more
wiley   +1 more source

Acute Post‐Partum Psychosis and Dystonia Reveals Late‐Onset MPAN

open access: yes
Movement Disorders Clinical Practice, EarlyView.
Mathilde Lachaume   +7 more
wiley   +1 more source

Levodopa and Melanoma: Practical Recommendations for Parkinson's Disease—International Parkinson and Movement Disorder Society Scientific Issues Committee Viewpoint

open access: yes
Movement Disorders Clinical Practice, EarlyView.
Giorgia Sciacca   +27 more
wiley   +1 more source

A Gap Analysis of Deep Brain Stimulation for Childhood‐Onset Movement Disorders

open access: yesMovement Disorders, EarlyView.
Abstract Background Deep brain stimulation (DBS) is an established and increasingly utilized therapy for childhood‐onset movement disorders. However, pediatric DBS poses unique challenges that are not adequately addressed by adult‐derived paradigms. Objective To identify key gaps in the current use of DBS in childhood‐onset movement disorders and to ...
Daniela Munoz‐Chesta   +6 more
wiley   +1 more source

Challenges of Pain in Parkinson's Disease: Results from the OCEAN Study

open access: yesMovement Disorders, EarlyView.
Abstract Background Pain is a common non‐motor symptom in Parkinson’s disease (PD) and is often associated to fluctuations. Objective The OpiCapone Effect on motor fluctuations and pAiN (OCEAN) study evaluated the effect of opicapone on fluctuation‐related pain when added to levodopa therapy in PD patients.
Kallol Ray Chaudhuri   +13 more
wiley   +1 more source

Plasma p‐tau217 Versus p‐tau181 in Parkinson's Disease: Differential Associations with Alzheimer's Disease‐Related Neurostructural Changes and Cognitive Function

open access: yesMovement Disorders, EarlyView.
Abstract Background Plasma phosphorylated‐tau at threonine‐217 (p‐tau217) and threonine‐181 (p‐tau181) are scalable, minimally invasive biomarkers of Alzheimer's disease (AD) pathology. In Parkinson's disease (PD), AD co‐pathology may contribute to its clinical heterogeneity.
Eleonora Fiorenzato   +16 more
wiley   +1 more source

A Phase 1 Study of Convection‐Enhanced Delivery of Intraputaminal AAV2‐GDNF in Advanced Parkinson's Disease

open access: yesMovement Disorders, EarlyView.
Abstract Background Parkinson's disease (PD) is a progressive neurodegenerative disorder. Neurotrophic therapeutic approaches have been limited in part by incomplete delivery to the putamen. We developed image‐guided convection‐enhanced delivery with real‐time monitoring to improve intraputaminal distribution of neurotrophic gene therapy. Objectives To
John D. Heiss   +10 more
wiley   +1 more source

Spatiotemporal Progression Patterns of Striatal Dopamine Depletion and Cerebral Hypoperfusion in Parkinson's Disease

open access: yesMovement Disorders, EarlyView.
Abstract Background The identification of Parkinson's disease (PD) subtypes is crucial for predicting the disease course and designing personalized therapeutic strategies. Objectives The aim of the study was to characterize the heterogeneity of the spatiotemporal evolutionary patterns of striatal dopamine depletion and cerebral hypoperfusion in PD ...
Yeeun Sun   +9 more
wiley   +1 more source

Melanopsin‐Mediated Post‐Illumination Pupillary Response in Idiopathic Rapid Eye Movement (REM) Sleep Behavior Disorder and Parkinson's Disease

open access: yesMovement Disorders, EarlyView.
Abstract Aims To conduct a case–control study to investigate melanopsin‐mediated post‐illumination pupillary response (PIPR) in patients with Parkinson's disease (PD), video‐polysomnography‐confirmed isolated/idiopathic rapid eye movement (REM) sleep behavior disorder (iRBD), and age‐matched healthy controls (HC). Methods PIPR was measured at 6 s after
Joey W.Y. Chan   +16 more
wiley   +1 more source

Hyperhomocysteinemia and Vitamin B Deficiency as Potential Aggravating Factors in Huntington's Disease: A Prospective Monocentric Study

open access: yesMovement Disorders, EarlyView.
Abstract Background Although not confirmed, some studies have suggested that elevated homocysteine levels are common in patients with Huntington's disease (HD). Its clinical relevance remains unclear. Objectives We aimed to assess vitamin B and homocysteine levels in HD patients and explore the relationships among hyperhomocysteinemia, vitamin B ...
Salomé Puisieux   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy